Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Surface Oncology, Inc. - Common Stock (NQ: SURF )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Surface Oncology, Inc. - Common Stock

< Previous 1 2 3 Next >
Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences
Urges Stockholders to Vote Promptly to Ensure Their Shares are Represented at the September 7th Special Meeting 
From Surface Oncology, Inc.
Via GlobeNewswire
SURFACE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surface Oncology, Inc. - SURF
From Kahn Swick & Foti, LLC
Via Business Wire
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023
From Surface Oncology, Inc.
Via GlobeNewswire
Health Care Company Coherus BioSciences Announces Merger With Surface Oncology
Via Benzinga
Recap: Surface Oncology Q1 Earnings
Via Benzinga
Downgrade Aside, Cathie Wood Buys $1.2M Worth Of SoFi Shares
Via Benzinga
Cathie Wood's Ark Pours $3.3M More Into This Chipmaker Amid AI Frenzy: Here Are Other Major Monday Trades
Via Benzinga
Cathie Wood's Ark Outshines S&P 500, Nasdaq In H1: Here Are The Major Trades It Made
Via Benzinga
Cathie Wood Sells $7M Tesla Stock Friday Amid Pullback, Bets Big On This Crypto-Linked Stock
Via Benzinga
SURFACE ONCOLOGY INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surface Oncology, Inc. - SURF
From Kahn Swick & Foti, LLC
Via Business Wire
Synergy Of Coherus And Surface Oncology: Analyst Forecasts $50M Savings And 2024 Profitability
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating on the shares of Coherus BioSciences, Inc. 
Via Benzinga
Nasdaq Down 80 Points; US Consumer Sentiment Surges To 4-Month High In June
U.S. stocks traded lower toward the end of trading, with Nasdaq Compsoite dropping around 80 points on Friday. The Dow traded down 0.24% to 34,324.18 while the NASDAQ fell 0.59% to 13,701.06. The S&P... 
Via Benzinga
Crude Oil Rises; Adobe Posts Upbeat Results
U.S. stocks traded slightly higher midway through trading, with Dow Jones gaining around 20 points on Friday. The Dow traded up 0.06% to 34,428.13 while the NASDAQ rose 0.05% to 13,789.23. The S&P 500,... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 20, 2023
Via Benzinga
Coherus BioSciences, MicroVision, Millicom And Other Big Stocks Moving Lower On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording losses in today’s session. Coherus BioSciences, Inc. (NASDAQ: CHRS) tumbled 16.8%... 
Via Benzinga
Why Squarespace Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Oncorus, Inc. (NASDAQ: ONCR) shares surged 258% to $0.2781. 
Via Benzinga
SURF Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Surface Oncology, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
US Stocks Mixed; Dow Gains 50 Points
U.S. stocks traded mixed this morning, with Dow Jones gaining around 50 points on Friday. Following the market opening Friday, the Dow traded up 0.16% to 34,464.01 while the NASDAQ fell 0.14% to... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Coherus BioSciences Acquires Small Immuno-Oncology Player Surface Oncology For $40M
Coherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that  
Via Benzinga
Coherus to Acquire Surface Oncology
From Surface Oncology, Inc.
Via GlobeNewswire
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2023
From Surface Oncology, Inc.
Via GlobeNewswire
Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023
– New in vivo data show SRF114 promotes a pro-inflammatory tumor microenvironment resulting in robust antitumor activity in mouse models – 
From Surface Oncology, Inc.
Via GlobeNewswire
Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023
From Surface Oncology, Inc.
Via GlobeNewswire
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022
From Surface Oncology, Inc.
Via GlobeNewswire
Surface Oncology to Participate in the Cowen 43rd Annual Health Care Conference
From Surface Oncology, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Surface Oncology to Participate in the 2023 Guggenheim Oncology Days Conference
From Surface Oncology, Inc.
Via GlobeNewswire
The 3 Best Biotech Stocks Under $1 to Buy for January
Even the best small biotech stocks can go bust on a single bad study, but the winners can make their early investors rich. 
Via InvestorPlace
Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology
Surface Oncology initiates clinical trial with antibody discovered using Vaccinex’s ActivMAb® Antibody Discovery Platform 
From Vaccinex, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.